Role of Ulinastatin in Preventing Severe Sepsis and Consequent Morbidities and Mortality (MUNI-SEP)
Severe Sepsis, Septic Shock, MODS
About this trial
This is an interventional prevention trial for Severe Sepsis
Eligibility Criteria
Inclusion Criteria: Age >18 or <60 Sepsis, and severe sepsis, as defined in operational definitions Patients voluntarily agreed to participate in the study after informed consent Exclusion Criteria: Fulminant hepatic failure Acute cerebrovascular accidents Acute poisoning Chronic Kidney Disease stage 5 Diagnosed case of immune thrombocytopenia Low output cardiac failure, with left ventricular ejection fraction <20% Advance chronic obstructive pulmonary disease on long term oxygen therapy Lactation or pregnancy
Sites / Locations
- Medical ICU, Jinnah Postgraduate Medical CentreRecruiting
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Control Group Arm
Active Intervention Arm
Standard of care treatment arm, study medication will not be given
This group will receive Nine MiU Ulinastatin in three divided doses 8 hourly